Artificial sweeteners in relation to the epidemiology of bladder cancer

Toxicological aspects of cyclamate and cyclohexylamine

In the late 1960s the artificial sweetener cyclamate was implicated as a bladder carcinogen in rats. This finding and other concerns about its safety ultimately led to a ban on cyclamate in the U.S. and restrictions on its use in many other countries. Since that time, the carcinogenic potential of cyclamate and cyclohexylamine, its principal metabolite, has been reevaluated in a group of well-controlled, well-designed bioassays that have failed to substantiate the earlier findings. This review of the published and unpublished literature on cyclamate attempts to evaluate the carcinogenicity question and other important aspects of the toxicity of cyclamate and cyclohexylamine, including their effects on various organ systems, their genotoxic potential, and their effects on reproduction. In addition, the physiological disposition of cyclamate is reviewed, with particular attention directed toward the site and extent of its conversion to cyclohexylamine.

A review of epidemiological studies on artificial sweeteners and bladder cancer

Next to tobacco, saccharin may be the substance that has been most studied epidemiologically. Over 5000 patients with bladder cancer have participated in case-control studies; over 27,000 diabetics have been observed for 234,000 person-years. The summary relative risk from combining all case-control studies is less than 0.98, the standardized mortality ratio for bladder cancer in diabetics is only 70. Analysis of these studies leads to the conclusion that saccharin is not related to human bladder cancer.